A. Tsodikov, R. Gulati, and E. Heijnsdijk, Reconciling the effects of screening on prostate cancer mortality in the ERSPC and PLCO trials, Ann Intern Med, vol.167, pp.449-55, 2017.

J. S. Chen, K. T. Chen, and W. C. Fan, Combined analysis of survivin autoantibody and carcinoembryonic antigen biomarkers for improved detection of colorectal cancer, Clin Chem Lab Med, vol.48, pp.719-744, 2010.

L. L. Song and Y. M. Li, Current noninvasive tests for colorectal cancer screening: an overview of colorectal cancer screening tests, World J Gastrointest Oncol, vol.8, pp.793-800, 2016.

A. Dhaliwal, P. J. Vlachostergios, and K. G. Oikonomou, Fecal DNA testing for colorectal cancer screening: molecular targets and perspectives, World J Gastrointest Oncol, vol.7, pp.178-83, 2015.

T. F. Imperiale, D. F. Ransohoff, and S. H. Itzkowitz, Fecal DNA versus fecal occult blood for colorectal-cancer screening in an average-risk population, N Engl J Med, vol.351, pp.2704-2718, 2004.

T. F. Imperiale, D. F. Ransohoff, and S. H. Itzkowitz, Multitarget stool DNA testing for colorectal-cancer screening, N Engl J Med, vol.370, pp.1287-97, 2014.

, NCI dictionary of cancer terms Natl Cancer Inst nd

P. Mandel and P. Metais, Les acides nucléiques du plasma sanguin chez l'homme, CR Seances Soc Biol Fil, vol.142, pp.241-244, 1948.

M. Stroun, P. Anker, and J. Lyautey, Isolation and characterization of DNA from the plasma of cancer patients, Eur J Cancer Clin Oncol, vol.23, pp.707-719, 1987.

A. R. Thierry, S. Messaoudi, . El, and P. B. Gahan, Origins, structures, and functions of circulating DNA in oncology, Cancer Metastasis Rev, vol.35, pp.347-76, 2016.

M. Ilie, V. Hofman, and E. Long, Current challenges for detection of

L. D. Maxim, R. Niebo, and M. J. Utell, Screening tests: a review with examples, Inhal Toxicol, vol.26, pp.811-839, 2014.

J. Wilson and G. Jungner, Principles and practice of screening for disease, Geneva : World Health Organisation, vol.164, 1968.

A. Andermann, I. Blancquaert, and S. Beauchamp, Revisiting Wilson and Jungner in the genomic age: a review of screening criteria over the past 40 years, Bull World Health Organ, vol.86, pp.317-336, 2008.

K. Hajian-tilaki, Receiver operating characteristic (ROC) curve analysis for medical diagnostic test evaluation, Casp J Intern Med, vol.4, pp.627-662, 2013.

M. H. Mayrand, E. Duarte-franco, and I. Rodrigues, Human papillomavirus DNA versus Papanicolaou screening tests for cervical cancer, N Engl J Med, vol.357, pp.1579-88, 2007.

P. Stieber, D. Nagel, and I. Blankenburg, Diagnostic efficacy of CA 15-3 and CEA in the early detection of metastatic breast cancer: a retrospective analysis of kinetics on 743 breast cancer patients, Clin Chim Acta, vol.448, pp.228-259, 2015.

W. J. Catalona, D. S. Smith, and T. L. Ratliff, Measurement of prostate-specific antigen in serum as a screening test for prostate cancer, N Engl J Med, vol.324, pp.1156-61, 1991.

G. L. Andriole, E. D. Crawford, and R. L. Grubb, Mortality results from a randomized prostate-cancer screening trial, N Engl J Med, vol.360, pp.1310-1329, 2009.

F. H. Schröder, J. Hugosson, and M. J. Roobol, Screening and prostate-cancer mortality in a randomized European study, N Engl J Med, vol.360, pp.1320-1348, 2009.

J. Phallen, M. Sausen, and V. Adleff, Direct detection of early-stage cancers using circulating tumor DNA, Sci Transl Med, vol.9, p.2415, 2017.

L. Fernandez-cuesta, S. Perdomo, and P. H. Avogbe, Identification of circulating tumor DNA for the early detection of small-cell lung cancer, EBioMedicine, vol.10, pp.117-140, 2016.

J. D. Cohen, L. Li, and Y. Wang, Detection and localization of surgically resectable cancers with a multi-analyte blood test, Science, p.3247, 2018.

K. Chan, J. Woo, and A. King, Analysis of plasma Epstein-Barr virus DNA to screen for nasopharyngeal cancer, N Engl J Med, vol.377, pp.513-535, 2017.

F. Mouliere, B. Robert, and E. A. Peyrotte, High fragmentation characterizes tumour-derived circulating DNA, PLoS One, vol.6, 2011.

G. Leszinski, J. Lehner, and U. Gezer, Increased DNA integrity in colorectal cancer, In Vivo (Brooklyn), vol.28, pp.299-303, 2014.

A. Thierry and S. E. Messaoudi, Methods for screening a subject for cancer

M. Wang, J. S. Shao, and G. , Effect of exosome biomarkers for diagnosis and prognosis of breast cancer patients, Clin Transl Oncol, pp.1-6, 2017.

S. Loeb and W. J. Catalona, The prostate health index: a new test for the detection of prostate cancer, Ther Adv Urol, vol.6, pp.74-81, 2014.

B. Jordan, Dépister les cancers asymptotiques ?, Med Sci, vol.34, pp.363-368, 2018.

L. Wang, C. Wu, and L. Qiao, Clinical significance of folate receptor-positive circulating tumor cells detected by ligand-targeted polymerase chain reaction in lung cancer, J Cancer, vol.8, pp.104-114, 2017.

L. A. Diaz and A. Bardelli, Liquid biopsies: genotyping circulating tumor DNA, J Clin Oncol, vol.32, pp.579-86, 2014.

M. B. Freidin, D. Freydina, and M. Leung, Circulating tumor DNA outperforms circulating tumor cells for KRAS mutation detection in thoracic malignancies, Clin Chem, vol.61, pp.1299-304, 2015.

A. , C. Pantel, and K. , Characterization of single circulating tumor cells, FEBS Lett, vol.591, pp.2241-50, 2017.
URL : https://hal.archives-ouvertes.fr/hal-01762116

C. Roth, B. Rack, and V. Müller, Circulating microRNAs as blood-based markers for patients with primary and metastatic breast cancer, Breast Cancer Res, vol.12, p.90, 2010.

A. R. Kodahl, M. B. Lyng, and H. Binder, Novel circulating microRNA signature as a potential noninvasive multi-marker test in ER-positive early-stage breast cancer: a case control study, Mol Oncol, vol.8, pp.874-83, 2014.

M. Tomasetti, M. Amati, and J. Neuzil, Circulating epigenetic biomarkers in lung malignancies: from early diagnosis to therapy, Lung Cancer, vol.107, pp.65-72, 2017.

D. L. Adams, D. K. Adams, and R. K. Alpaugh, Circulating cancer-associated macrophage-like cells differentiate malignant breast cancer and benign breast conditions, Cancer Epidemiol Prev Biomarkers, vol.25, pp.1037-1079, 2016.

R. M. Gonzalez, D. S. Daly, and R. Tan, Plasma biomarker profiles differ depending on breast cancer subtype but RANTES is consistently increased, Cancer Epidemiol Biomarkers Prev, vol.20, pp.1543-51, 2011.

N. Sol and T. Wurdinger, Platelet RNA signatures for the detection of cancer, Cancer Metastasis Rev, pp.1-10, 2017.